Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 3/20 | 0.53 |
| ▸ | MMP12 | P39900 | 3/20 | 0.53 |
| ▸ | MMP14 | P50281 | 3/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796610 | 0.90 | NOD1 (0.58) | CASP2NOD1NAAAGLP1R | |
| SCHEMBL26743907 | 0.89 | NOD1 (0.67) | NOD1GLP1R | |
| SCHEMBL29299841 | 0.88 | FOLH1 (0.43) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL13461485 | 0.85 | CASP2 (0.54) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL15783568 | 0.84 | CASP2 (0.56) | MMP2MMP9MMP8MMP12MMP14 | |
| Hydrochloric Acid SCHEMBL23834203 | 0.83 | CASP2 (0.54) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL24217609 | 0.83 | EPHX1 (0.50) | CASP2NOD1NAAAEPHX1 | |
| SCHEMBL6036687 | 0.83 | NOD1 (0.64) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL21389120 | 0.83 | NOD1 (0.63) | NOD1GLP1R | |
| SCHEMBL21389084 | 0.82 | NOD1 (0.62) | NOD1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | MMP2 1790/4885MMP9 2090/4885MMP8 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.